Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

卷:85

Article

Nakagawa, Hidemi¹  Nemoto, Osamu²  Igarashi, Atsuyuki³  Saeki, Hidehisa⁴  Kabashima, Kenji⁵  Nagata, Takeshi⁶ 

[1] Jikei Univ, Sch Med, Tokyo, Japan

[2] Kojinkai Sapporo Skin Clin, Sapporo, Hokkaido, Japan

[3] NTT Med Ctr Tokyo, Dept Dermatol, Tokyo, Japan

[4] Nippon Med Sch, Dept Dermatol, Tokyo, Japan

[5] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan

[6] Japan Tobacco Inc, Pharmaceut Div, Tokyo, Japan

关键词: atopic dermatitis;    delgocitinib;    eczema;    Janus kinase;    JAK inhibitor;    JTE-052;    ointment;    pediatric patients;    pruritus;    skin barrier;    topical therapy;   

DOI  :  10.1016/j.jaad.2021.06.014

来源: Elsevier

【 摘 要 】

Background: Delgocitinib 0.5% ointment, a topical Janus kinase inhibitor, has been approved in Japan for adult patients with atopic dermatitis (AD). Objective: To evaluate the efficacy and safety of delgocitinib ointment in pediatric patients with AD. Methods: Part 1 of this study was a 4-week double-blind period in which Japanese patients aged 2 through 15 years were randomized in a 1:1 ratio to delgocitinib 0.25% ointment or vehicle ointment. Part 2 was a 52 week extension period. Eligible patients entered part 2 to receive 0.25% or 0.5% delgocitinib ointment. Results: At the initiation of the study, approximately half of the patients had moderate AD. At the end of treatment in part 1, the least-squares mean percent change from baseline in modified Eczema Area and Severity Index score, the primary efficacy endpoint, was significantly greater for delgocitinib ointment than for vehicle (-39.3% vs +10.9%, P < .001). In part 2, improvements in AD were also seen through week 56. Most adverse events were mild and unrelated to delgocitinib across the study periods. Limitations: Only Japanese patients were included. In part 2, no control group was included and rescue therapy was allowed. Conclusion: Delgocitinib ointment was effective and well tolerated when applied to Japanese pediatric patients with AD for up to 56 weeks.

【 授权许可】

Free